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An Engineered Calmodulin-Based Allosteric 
Switch for Peptide Biosensing 
Glenna E. Meister and Neel S. Joshi*
[a,b] 
 
This work describes the development of a new platform for allosteric 
protein engineering that takes advantage of the ability of calmodulin 
to change conformation upon binding to peptide and protein ligands. 
The switch we have developed consists of a fusion protein in which 
calmodulin is genetically inserted into the sequence of TEM1 β-
lactamase. In this approach, calmodulin acts as the input domain, 
whose ligand-dependent conformational changes control the activity 
of the β-lactamase output domain. The new allosteric enzyme exhibits 
up to 120 times higher catalytic activity in the activated (peptide 
bound) state compared to the inactive (no peptide bound) state in 
vitro. Activation of the enzyme is ligand-dependent – peptides with 
higher affinities for wild-type calmodulin exhibit increased switch 
activity. Calmodulin’s ability to “turn on” the activity of β-lactamase 
makes this a potentially valuable scaffold for the directed evolution of 
highly specific biosensors for detecting toxins and other clinically 
relevant biomarkers.
Introduction 
The development of new technologies for molecular sensing and 
signal  transduction  is  critical  to  advancements  in  fields  of 
synthetic biology,
[1] medical diagnostics,
[2] and environmental data 
collection
[3] among others. At the most basic level, a molecular 
sensor should be able to couple two distinct functions: specific 
molecular  recognition  (input)  and  generation  of  a  readily 
detectable signal (output). Although there exist various methods 
to accomplish this using advanced analytical techniques such as 
immunoassays,  biology  relies  heavily  on  allosteric  systems  for 
cellular sensing and signal transduction. Here we broadly define 
an allosteric system as any protein whose activity is modulated by 
a  binding  event  at  a  location  distinct  from  the  active  site.  The 
study  of  biological  signaling  has  inspired  new  methods  to 
engineer  allosteric  systems,
[4]  especially  those  that  can  sense 
biomedically  relevant  targets
[5]  or  interface  with  established 
signaling mechanisms in whole cells or organisms.
[6]  
The complexities of protein design have made it difficult to 
construct  allosteric  systems  de  novo,  but  researchers  have 
circumvented  this  problem  by  separating  the  input  and  output 
functions  into  separate  but  coupled  domains.  In  this  type  of 
approach, an ideal input domain is one that undergoes large but 
predictable  conformational  changes  upon  target  binding.  The 
input domain is then fused to an output domain in such a way that 
the  function  (i.e.  signal  generation)  of  the  output  domain  is 
conformationally  dependent.  Despite  the  abundance  of 
engineered  allosteric  enzymes  and  sensors  present  in  the 
literature,
[7]  few  are  designed  to  respond  to  protein  or  peptide-
based binding targets
[8] – rather, most are activated by ions and 
small  molecules.
[7b]  Nevertheless,  there  is  great  interest  in 
developing  sensors  for  peptides  and  proteins  because  of  their 
central role in cellular signaling. More widespread use of these 
techniques is hindered by other barriers, such as output signals 
that  are  limited  to  FRET  or  the  need  to  painstakingly  optimize 
fusion  points  for  the  desired  output  protein,  which  can  require 
screening of large libraries of randomized fusion points.
[9] 
Here we report the rational design and development of a 
new  allosteric  switch  protein  that  responds  to  peptide-based 
binding  targets.  Based  on  the  relatively  straightforward 
optimization  of  the  switch  compared  to  related  examples,  our 
design could represent a promising platform for modular switch 
development. The switch we have developed (BLACaM) makes 
use  of  the  domain  insertion  technique
[7a]  and  consists  of 
calmodulin  (CaM)  inserted  into  the  sequence  of  TEM1  β-
lactamase  (BLA,  EC  3.5.2.6).  BLACaM  is  controlled  by  the 
conformational changes of the CaM input domain. CaM is a small 
(~17  kDa)  globular  protein  that  exists  in  three  conformational 
states. In the absence of Ca
2+, it adopts a “closed” conformation 
with its N- and C-termini spatially separated by only 9 Å. In the 
presence of Ca
2+, CaM adopts an “open” conformation with the 
termini separated by ~31 Å. In the presence of Ca
2+ and a peptide 
binding target, CaM once again adopts a “closed” conformation 
(Figure 1a). The target-bound forms of CaM for different peptides 
are similar but not identical and structural data suggests that the 
distance  between  the  termini  may  vary  between  13-24  Å  for 
different targets. Because of its well-characterized conformational 
dynamics,  CaM  has  been  used  in  molecular  sensors  such  as 
genetically encodable calcium sensors for decades. However, its 
ability to bind with high affinity to proteins and peptides has yet to 
be exploited in allosteric biosensors. Here we show that the new 
switch,  BLACaM,  is  mostly  inactive  when  Ca
2+  is  present,  and 
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becomes  activated  after  binding  to  a  range  of  target  peptides. 
The switch demonstrates specificity in that it is only activated by 
peptides that are known to bind to wt-CaM.  
 
Figure  1.  Calmodulin  (CaM)  and  TEM1  β-lactamase  (BLA)  structures.  a) 
Structures  showing  the  conformation  changes  of  CaM  in  the  apo,  or  closed 
state (pdb ID: 1CFD), calcium bound, or open state (PDB ID: 1CLL), and bound 
to calcium and the M13 peptide (PDB ID: 2BBM). b) Structure of the TEM1 β-
lactamase (PDB ID: 1BTL) with the protein complementation fragments BLF1 
and BLF2 shown in purple and green, respectively. The insertion points for all 
switch constructs are indicated with arrows and labelled orange.   
Results and Discussion 
Calmodulin – TEM1 β-lactamase fusions 
Previous attempts at switch engineering using domain insertion 
required high throughput screening techniques in order to identify 
a  suitable  insertion  point.
[9-10]  We  sought  to  avoid  the  time 
consuming process of library construction associated with most 
domain insertion efforts by making use of the known split points 
of  TEM1  β-lactamase  (BLA).  Therefore,  we  synthesized  eight 
BLACaM  variants  using  the  BLA  split  points  reported  by 
Galarneau et.al.
[11] and Guntas et. al.
[9, 12]  (Figure 1b). We initially 
constructed  genes  encoding  for  a  small  panel  of  BLACaM 
variants  (P1-P8,  Figure  S1).  P1  and  P2  consisted  of  the  N-
terminal  fragment  of  BLA(1-194)  (a.k.a.  BLF1)  fused  to  the  N-
terminus of CaM, and the C-terminal fragment of BLA (196-286) 
(a.k.a. BLF2) fused to the C-terminus of CaM, while P3 and P4 
had the order of the domains reversed. P5/P6 and P7/P8 were 
analogous  to  P1/P2  and  P3/P4,  respectively,  except  we  used 
insertion points  identified by Guntas, et al. in the construction of 
a  maltose  binding  protein–β-lactamase  switch.
[9,  12]  Our  panel 
included constructs that had no linkers (direct fusion), two very 
short linkers (S and SG), and constructs that used both a short 
stiff  linker  (DKS)  and  a  short  flexible  linker  (GSGGG).  We 
rationalized that the Galarneau, et al. split points would be good 
initial  insertion  points  because  the  fragments  had  been  pre-
optimized to: 1) resist spontaneous association in solution, and 2) 
be individually non-functional but reconstitute an active enzyme 
when brought in close proximity to one another by fused domains. 
Additionally, the Guntas, et al. split points, which were identified 
using  a  large  library  (10
6  members)  screening  process,  have 
already been proven to be suitable insertion sites that allow for 
modulation  of  the  BLA  activity.  We  reasoned  that  the  open 
conformation of CaM inserted at these points would be able to 
separate the two BLA fragments enough to inactivate them. Once 
CaM adopted a closed conformation in response to ligand binding, 
the  two  β-lactamase  fragments  would  be  brought  together  to 
activate the enzyme.  
The P1-P8 domain insertion variants were initially screened 
for switching activity in crude cellular lysates. To do this, plasmids 
encoding for each variant were separately transformed into E. coli 
and overexpression was induced. Following induction, the cells 
were  lysed  and  the  switching  properties  of  the  variants  were 
assayed  directly  in  the  clarified  lysate  using  a  colorimetric 
indicator (nitrocefin) for BLA activity. The screening process for 
switching  activity  was  performed  by  monitoring  each  variant’s 
BLA activity under sets of conditions known to induce the three 
different conformational states of wt-CaM (Figure 1a): no calcium 
or target (1 mM EGTA), calcium only (5 mM Ca
2+), and calcium 
plus peptide target (5 mM Ca
2+, 1 µM target). The target in this 
case was the calmodulin binding peptide M13, a 26 amino acid 
peptide derived from myosin light chain kinase that is known to 
bind to and induce the “closed” conformation of CaM.
[13] Based on 
the activity assays, the variants were classified into three types: 
always  on  (P1  and  P3),  always  off  (P2,  P5,  P7  and  P8),  and 
switch  (P4  and  P6)  (Figure  2).  The  P4  variant  exhibited  “on” 
states in both the non-calcium bound and M13 bound states with 
activity close to baseline (“off”) in the presence of calcium while 
the P6 variant only showed increased activity in the M13 bound 
state. Notably, both P1 and P3 did exhibit higher activity under 
the EGTA and M13-bound conditions, but also showed significant 
activity under the calcium only conditions. Furthermore, the range 
of responses observed for the variants even in this small panel 
highlights the importance of insertion point and linker flexibility for 
effective switch construction. We theorized that too much linker 
flexibility would allow the BLA fragments to associate regardless 
of  the  conformational  state  of  the  CaM  domain,  effectively 
decoupling input from output, while rigid linkers or no linkers may 
confine the BLA fragments in orientations that do not allow them 
to  re-associate  properly.  Performing  the  screen  in  lysates  also 
enabled  us  to  probe  the  specificity  of  the  switch.  Variants 
identified as “hits” had to respond specifically to the target peptide 
in the presence of the complex lysate mixture, which contained 
proteins, DNA, RNA, lipids, and small molecules.  
Figure 2. Activity assays for constructs P1-P8 in crude cellular lysates. Total 
nitrocefin turnover after 7 minutes was monitored at 492 nm for each construct. 
Absorbance values are normalized with respect to lysates from cells expressing 
wt-CaM alone. 
 
BLACaM switch purification and characterization 
Based on the switching activity observed in the lysate assays, the 
P4 variant (hereafter referred to as BLACaM) was selected for 
further  characterization  (Figure  3b).  While  the  P6  fusion  also 
exhibited  higher  activity  when  bound  to  M13  (but  not  in  the 
presence of EGTA), this switch was found to be highly toxic to E. 
coli cells even in low amounts and was not characterized further.   3 
 
Figure 3. a) Schematic of the BLACaM construct in various conformational states – in the absence of calcium, in the presence of calcium, and bound to calcium and 
the target peptide M13. b) Schematic of the BLACaM gene construct compared to that of truncation mutants BLF2-CaM and CaM-BLF1. Activity assays were 
conducted with the CENTA substrate in the presence of 125 nM of either BLACaM (c) or BLF2-CaM and CaM-BLF1 (d) incubated with 5 mM calcium and 500 nM 
M13 (red), 1 mM EGTA (blue) or 5 mM calcium only (black dashed). 
The BLACaM switch also seemed to exhibit a low level of toxicity 
in E. coli cells, however we were able to obtain sufficient amounts 
of  BLACaM  using  a  T7  promoter  by  expressing  at  a  lower 
temperature (18°C) and subsequently purifying using a C-terminal 
6xHis  tag.  SDS-PAGE  characterization  of  the  affinity-purified 
samples  revealed  that  there  was  extensive  truncation  of  the 
protein, possibly resulting from the translation of short fragments 
from internal start codons. The calm1 gene encoding for the CaM 
domain  originated  from  humans,  and  consequently  contained 
several non-optimal codons for E. coli that we believe enabled the 
use of internal start codons and hindered the full translation of 
BLACaM. Therefore, we altered the gene to include only those 
codons common in E. coli,  allowing  for  isolation  of  a  BLACaM 
sample  that  was  ≥95%  pure  after  His-tag  affinity  purification 
(Figure S2).  
The  purified  BLACaM  protein  was  then  characterized  in 
vitro to determine its switching activity with different analytes. For 
these  experiments,  activity  was  measured  by  tracking  the 
hydrolysis  of  a  commercially  available  BLA  substrate 
(CENTA™).
[14]  In  order  to  confirm  our  hypothesis  about  the 
mechanism  of  switch  activation,  we  ran  several  control 
experiments  to  monitor  the  activity  of  BLACaM  sub-domains 
individually. The wt-BLA alone established a baseline for enzyme 
activity, while wt-CaM alone was not active under any conditions, 
as expected (Figure S3a). Notably, the activity of pure BLA was 
decreased slightly in the presence of EGTA. Neither wt-BLA nor 
wt-CaM was affected by the presence of the target peptide, M13 
(Figure S3b). Finally, we conducted activity assays with wt-BLA 
and wt-CaM together in one pot in the presence of a variety of 
peptides.  In  total,  the  control  experiments  confirmed  three 
important points: 1) on its own, BLA is largely unaffected by the 
various conditions expected to induce switching in BLACaM; 2) 
the  CaM  domain  does  not  exhibit  any  ability  to  hydrolyze  the 
CENTA  substrate;  3)  points  1  and  2  are  not  affected  by  non-
covalent  interactions  between  BLA  and  CaM  under  any  of  the 
tested conditions.  
With a clear understanding of the behavior of the wild-type 
proteins,  we  proceeded  to  characterize  the  purified  BLACaM 
switch. As expected from the lysate assays, BLACaM exhibited 
ligand-dependent  activity.  In  a  purely  qualitative  sense,  it  was 
immediately clear that BLACaM was only moderately active in the 
absence of calcium (EGTA), mostly inactive in the presence of 
Ca
2+  only, and highly active in the presence of Ca
2+  plus M13 
(Figure 3a,c). Notably, BLACaM exhibits much higher switching 
activity when pure compared to when in crude lysate. Also, while 
the EGTA and Ca
2+ plus M13 states appear to be equally active 
in  lysates,  they  are  quite  different  when  pure,  suggesting  that 
complex mixtures could have unexpected effects on the switch 
behavior.  
 
BLACaM  activity  is  due  to  intramolecular  interactions  of 
BLF1 and BLF2 
In a final set of control experiments we wanted to confirm that 
switch  activity  was  not  a  result  of  multimerization  of  BLACaM 
during  the  activity  assays.  Although  the  split  BLA  fragments 
(BLF1 and BLF2) are designed to have a sufficiently high Kd so 
as not associate at low concentrations, they can spontaneously 
refold  through  intermolecular  interactions  at  sufficiently  high 
concentrations. Therefore, we constructed two truncation mutants 
of  BLACaM  (Figure  3b),  one  with  the  BLF1  fragment  removed 
(BLF2-CaM)  and  one  with  the  BLF2  fragment  removed  (CaM-
BLF1).  In  order  to  probe  the  potential  for  intermolecular 
complementation  to  contribute  to  the  observed  activity  of 
BLACaM, the two truncated mutants were combined at various 
equimolar concentrations and subjected to activity assays. Some 
complementation did occur at concentrations above 1 µM (Figure 
S4c),  but  no  significant  substrate  turnover  was  observed  at 
concentrations  that  were  used  for  the  BLACaM  activity  assays 
(125 nM) (Figure 3d).  
Based on these experiments, it is clear that multimerization 
was not a factor in the switching activity experiments. However, it 
should  be  noted  that  the  switch  needed  to  be  “primed”  by 
calcium-induced  inactivation  before  rigorous  switching  activity 
experiments could take place. BLACaM required 50+ minutes of 
incubation  with  Ca
2+  at  room  temperature  to  reach  its  lowest 
activity  levels  (Figure  S5a),  possibly  due  to  residual 
intramolecular fragment complementation. In contrast, after being 
in the “off”  state, the switch could be reactivated again in less 
than 5 minutes upon addition of the target peptide M13 (Figure 
S5b),  suggesting  that  fragment  association  from  an  unfolded 
state occurs much more rapidly than dissociation of the folded 
fragments.  It  is  known  that  certain  assisted  protein 
complementation  fragments  are  stabilized  in  their  fully  folded 
state,  which  could  explain  the  longer  times  required  for 
inactivation.
[15] Notably, the time required for switch inactivation 
was dramatically reduced by increases in temperature. BLACaM 
that was assayed following a 10 minute incubation with only Ca
2+ 
at  37°C  followed  by  re-equilibration  at  25°C  was  inactive,  but 
remained active when incubated with M13 (Figure S6a). Activity 
assays  performed  at  various  temperatures  confirmed  that 
BLACaM retains most of its activity up to 30°C in the EGTA or 
calcium plus peptide states. However, at 37°C, the switch loses    4 
all  activity  in  the  absence  of  calcium,  but  remains  marginally 
active  when  bound  to  the  target  peptide  (Figure  S6b,d).  This 
suggests  that  the  peptide-bound  conformation  of  CaM  helps 
stabilize  the  BLA  fragments,  which  may  contribute  to  the 
difference in observed activity between the EGTA and the Ca
2+ 
plus M13 conditions (Figure 3c).  
 
Switching Activity (SA) of BLACaM switch 
CaM is known to bind to a variety of peptide and protein targets, 
making it a potentially useful starting point for the design of input 
domains  with  greater  affinity  and  specificity  for  many  target 
analytes. Accordingly, we screened BLACaM switching activity in 
response to a panel of targets that spanned a range of binding 
affinities for wt-CaM. We defined a parameter SA as the ratio of 
the initial rates of substrate hydrolysis in the presence of calcium 
plus  the  target  (or  EGTA)  compared  to  the  mostly  inactive 
calcium bound state:  SA = V0 
peptide/V0
Calcium. 
Table 1 displays the SA values for BLACaM in response to 
a 4-fold molar excess of each peptide target. Peptide targets that 
are  known  to  bind  to  wt-CaM  with  high  affinities  (M13,
[16] 
mastoparan,
[17] melittin
[18]) exhibited SA values ranging from 100-
120.  Targets  with  moderate  affinity  for  wt-CaM  (NPY,
[19]  δ-
toxin
[20]) exhibited lower SA values. Finally, targets with no known 
affinity for CaM (LH-RH, angiotensin) had SA values close to 1. 
Additionally,  we  evaluated  the  effect  of  the  small  molecule 
trifluoperazine  (TFP),  which  is  known  to  cause  a  calcium-
dependent  conformational  change  in  CaM,
[21]  on  the  BLACaM 
switch. However, only a slight (~2-fold) increase in activity was 
observed. This data set supports the claim that the mechanism of 
switch  activation  is  through  ligand-induced  conformational 
changes  of  the  CaM-based  input  domain.  Among  the  target 
ligands that activate the allosteric switch are peptides that may be 
particularly useful as clinically relevant biomarkers. In particular, 
neuropeptide  Y  (NPY)  is  a  neurotransmitter  hormone  that  has 
been proposed as biomarker to monitor conditions ranging from 
anorexia
[22] to post traumatic stress disorder (PTSD).
[23] Similarly, 
δ-toxin is an endotoxin that is routinely used to identify virulent 
strains of S. aureus,
[24] an opportunistic pathogen responsible for 
many infections.  
 
Activity of the BLACaM switch is dose dependent 
In order to determine the sensitivity of the switch towards a target 
ligand, we monitored substrate hydrolysis rates for BLACaM at 
various concentrations of M13. A plot of initial rates versus M13 
concentration reveals that the peptide can be detected at tens of 
nanomolar concentrations and is dose dependent up to 150 nM 
(Figure 4). There was ~10-20% decrease in initial rates for M13 
concentrations  above  175  nM,  hindering  the  effectiveness  of 
traditional  Michaelis-Menten-type  kinetic  models  to  fit  the  data 
(data not shown). We attribute this rate decrease to aggregation 
of  M13,  which  is  a  known  problem  in  CaM  binding  assays 
because many canonical CaM binders are hydrophobic peptides 
prone to aggregation in aqueous solutions.
[20, 25]  
Figure 4. Initial rates of substrate hydrolysis as a function of M13 concentration 
for BLACaM in the presence of Ca
2+.  
Conclusion 
We have developed a new allosteric enzyme by inserting CaM 
into  a  previously  established  split  point  for  BLA.  In  contrast  to 
previous  attempts  to  create  allosteric  enzymes  by  domain 
insertion,  the  initial  identification  of  this  switch  structure  was 
accomplished without the need to synthesize and analyze large 
libraries  of  mutants.  Furthermore,  the  switch  is  activated  to 
various  degrees  (up  to  120-fold)  by  several  peptides  and  one 
small  molecule  target  with  reported  affinity  for  wt-CaM.  This 
magnitude of ligand-dependent activation is on par with the some 
of the highest values reported for both natural and engineered 
allosteric  enzymes.
[9]  This  represents  the  first  example  of  a 
calmodulin-based  allosteric  biosensor  designed  to  respond  to 
peptide targets. We anticipate that the BLACaM architecture will 
be  a  fruitful  starting  point  for  the  rational  design  or  directed 
evolution of new highly specific and sensitive biosensors for use 
inside cells and in vitro. 
Experimental Section 
General:    All  reagents  were  purchased  from  Sigma  and  all 
enzymes  from  New  England  Biolabs  unless  otherwise  noted. 
Molecular cloning techniques and protein analysis such as PCR 
and electrophoresis were performed as described in Sambrook 
and Russell.
[26]   
 
Table 1. Switching Activity of BLACaM in Response to Peptide Targets 
 
Peptide Sequence  Switching Activity 
(SA)
a 
# of Binding 
Sites 
Kd with  
wt-CaM 
Calcium only  N/A  1.0 ± 0.1  4  N/A 
EGTA  N/A  29 ± 2  -  N/A 
M13 (sm-MLCK fragment)  KRRWKKNFIAVSAANRFKKISSSGAL  110 ± 12  1  0.13 nM
b 
Mastoparan  INLKALAALAKKIL  120 ± 11  1  0.3 nM
b 
Melittin  GIGAVLKVLTTGLPALISWIKRKRQQ  100 ± 11  1  3 nM
b 
δ-toxin  MAQDIISTIGDLVKWIIDTVNKFTKK  16 ± 2  1 
c 
Neuropeptide Y (NPY)  YPSKPDNPGEDAPAEDMARYYSALRHYINLITRQRY  5.2 ± 0.7  1 
c 
Luteinizing Hormone- Releasing 
Hormone (LH-RH) 
pEHWSKGLRPG  0.97 ± 0.13  1  ---
d 
Angiotensin  DRVYIHPFHL  1.1 ± 0.1  1  ---
 d 
Trifluoperazine (TFP)  N/A  2.2 ± 0.3  4+  ---
e 
[a]  A  description  of  the  statistical  analysis  is  available  in  the  Supporting  Information.  [b]Published  dissociation  constants  for  CaM  binding  to  M13,
[16] 
mastoparan,
[17] and melittin.
[18] [c] While binding was confirmed for NPY
[19] and δ-toxin
[20] accurate Kd determinations were not done. [d] There is no known 
interaction between CaM and these peptides. [e] Multiple TFP molecules bind cooperatively to CaM.
[21]   5 
Gene Construction of Calmodulin and β-lactamase Fusions:  
Fusions of calmodulin and β-lactamase were created by overlap 
extension PCR using the Phusion® DNA Polymerase (NEB) and 
primers from either Eurofins MWG Operon or Bioneer Corp (see 
SI  Table  1).  All  restriction  enzymes  and  T4  DNA  ligase  were 
purchased from New England Biolabs. Cloning was performed in 
the Turbo electrocompetent cell line (New England Biolabs). The 
calmodulin  gene  (human  variant  calm1)  was  obtained  from 
Origene Technologies Inc. and TEM1 β-lactamase gene (bla) was 
cloned from the pDIMN2 vector.
[27]  
We  created  constructs  fusing  calmodulin  (CaM)  with 
TEM1 β-lactamase at four different fusion points: 1) the protein 
complementation assay (PCA) split points at BLA 194 and 196, 2) 
the BLA N- and C-termini using the (PCA) fragments,
[28] 3) fusion 
points  of  the  RG13,
[12]  and  4)  MBP317-347
[9]  maltose  binding 
protein(MBP)-BLA allosteric switches discovered by Guntas. PCR 
fragments of all BLA fragments were made using the TEM1 β-
lactamase gene from the pDIMN2 vector as a template and using 
primers  to  either  fuse  fragments  directly  to  CaM  or  with  short 
linkers DKS and GSGGG. The BLA fragments utilized for fusions 
P1-P4 were the PCA fragments BLF1 (BLA 24-194) and BLF2 
(BLA196-286),  for  fusions  P5-P6  were  fragments  from  RG13 
(BLA 24-226 and 227-286), and for P7 and P8 from MBP317-347 
(BLA 24-170 and BLA 170-286).  All fragments were created by 
PCR  using  the  following  primers  in  Table  S1.  The  human 
calmodulin gene, calm1, was amplified by PCR for fusion to BLA 
either directly or with described linkers. For ease of cloning, the 
later fusions (P5-P8) used either the DKS and GSGGG linkers or 
much shorter linkers of only S and SG to insert restriction sites of 
PstI and BspEI sites respectively. The various fragments of bla 
and calm1 DNA were then mixed together in equimolar amounts 
for an overlap extension PCR step and amplified with either BLA 
sig (BglII)-for and BLA-rev (P1 and P2), BLF2-for and BLF1-rev 
(P3 and P4), or  BLA24(BamHI)-for and BLA-rev (P5-P8) primers.  
Assembled  fragments  (see  Figure  S1)  were  then  gel  purified 
(Qiagen Gel Purification Kit) and digested with either BglII and 
SpeI or BamHI and SpeI for cloning into pDIMC8 vectors digested 
with  BamHI  and  SpeI.  Fragments  were  then  ligated  into  the 
digested  pDIMC8  vector  with  T4  DNA  ligase,  transformed  into 
Turbo  electrocompetent  cells  for  cloning,  and  then  into  DH5α 
cells for expression. Control vectors containing the wt-bla and wt-
calm1 genes were also created by amplifying the wild-type genes 
using  the  BLA  sig  (BglII)-for/BLA-rev  and  CalmI(BamHI)-
for/CalmI(SpeI)-rev  primers,  digesting  and  inserting  into  the 
pDIMC8 vector.  
 
Construction of BLACaM gene constructs and controls:  For 
purification  of  the  BLACaM  fusion,  an  optimized  version  of  the 
gene for expression in E. coli was designed using Gene Designer 
software from DNA 2.0 and synthesized by Biomatik. This gene 
version  was  cloned  into  the  pET30a  vector  (EMD  Millipore) 
appending  a  6x  His  tag.  All  controls  for  expression  were  also 
cloned  into  the  pET30a  vector  appending  the  6x  His  tag  and 
under control of a T7 promoter. CaM, BLA2-CaM, and CaM-BLA1 
controls  were  created  by  cloning  sections  of  the  optimized 
BLACaM gene using primer pairs BLA2opt-for/CaMopt(XhoI)-rev 
and  CaMopt-for/BLA1opt(XhoI)-rev  respectively.  A  wt-bla  gene 
was also inserted into the pET30a expression vector appending a 
6xHis tag for purification.   
 
BLACaM expression and purification: An optimized version of 
BLACaM  for  expression  in  E.  coli  in  the  pET30a  vector  (EMD 
Millapore) attached to a 6xHis tag and transformed into Shuffle 
T7 LysY cells (New England Biolabs). Cells were grown in LB 
media supplemented with 50 µg/ml kanamycin until an OD of 0.6-
0.8 at 30°C. Protein expression was then induced with 0.4 mM 
IPTG  and  expressed  at  18°C  for  14-16  hrs.    Cells  were 
resuspended in lysis buffer (50 mM Tris-CL, pH 7.4 with 300 mM 
NaCl,  20  mM  imidazole  and  cOmplete  EDTA-free  protease 
inhibitor cocktail (Roche)), lysed by sonication, and spun down to 
clarify lysate.  Before application to the gravity column with Ni-
NTA agarose (Qiagen), Tween-20 was added to the lysate to a 
1% concentration. Lysate was applied to the column equalibriated 
with 5 column volumes of 50 mM Tris-CL, pH 7.4 with 300 mM 
NaCl, 20 mM imidazole and 1% tween and washed with 5 column 
volumes of the same buffer after lysate application. Column was 
then  washed  with  an  additional  5  column  volumes  of  buffer 
without tween but containing 50 mM imidazole, and then eluted 
with 3 column volumes of buffer containing 150 mM imidazole.     
 
BLF2-CaM  and  CaM-BLF1  controls  expression  and 
purification:  pET30a  BLF2-CaM  vector  was  transformed  into 
BL21 (DE3) cells (Invitrogen) while the pET30a CaM-BLF1 vector 
was  transformed  into  SHuffle  T7  lysY  cells  (New  England 
Biolabs) for expression.  Controls were expressed  and  purified 
using  the  same  protocol  as  for  BLACaM  except  that  the 
BL21(DE3)  cells  were  originally  grown  at  37°C  instead  of  the 
30°C at which SHuffle T7 lysY cells are grown. 
 
Calmodulin  (CaM)  expression  and  purification:  The pET30a 
with optimized CaM was transformed into BL21 (DE3) cells and 
expressed  using  same  procedure  as  BLACaM.    Purification  of 
CaM was performed essentially as described by Gopalakrishna 
and Anderson.
[29]  
 
TEM1 β-lactamase (BLA) expression and purification: pET30a 
BLA was transformed into BL21 (DE3) cells for expression.  Cells 
were grown to an OD of 0.6-0.8 and induced with 0.4 mM IPTG.  
BLA was expressed at 37°C for 4 hours.  Protein was purified on 
a  Ni-NTA  agarose  column  in  protocol  similar  to  BLACaM, 
however no Tween-20 was used in any buffers.    
 
Lysate  Screening  Assays:  DH5α cells were transformed with  
pDIMC8  plasmids  with  various  CaM-BLA  fusion  constructs  as 
well as a plasmid containing wt-bla and wt-calm1 were grown in 
50  ml  LB  media  supplemented  with  50  µg/ml  chloramphenicol. 
Cells were grown at 37°C to an OD at 600nm to approximately 
0.5-0.6 and induced with 1 mM IPTG and protein was expressed 
for an additional 4 hours. Cells wre then spun down and frozen 
overnight. Cells were then resuspended in 2.5 ml lysis buffer (50 
mM Tris-CL, pH 7.5 and cOmplete EDTA-free protease inhibitor 
cocktail  (Roche))  and  cells  lysed  by  freeze/thaw  method  and 
clarified  by  centrifugation.  After  clarification,  the  lysates’  total 
protein concentrations were determined using the Bio-Rad Quick 
Start Bradford Protein Assay kit. Samples were diluted to a total 
protein concentration of ~ 725 µg/ml and 25 µl was mixed with 
100  µl  of  50  mM  Tris-Cl  buffer  with  mixtures  containing  final 
concentrations of either 1 mM EGTA, 5 mM CaCl2, or 5 mM CaCl 
2 plus 1 µM M13 peptide (N=3 for each condition).  Mixtures were 
then incubated for 1 hr at room temperature.  After incubation 100 
µl of  lysate mixture was transferred to another microassay plate 
with 5 µl of 4.25 mM nitrocefin substrate (EMD Millipore) in 50 
mM Tris-CL and mixed.  Absorbances at 492 nm were read ~25 
min after mixing on a Biotek Synergy H1 Hybrid plate reader. 
 
BLACaM Activity Assays: Assays were done in the presence of 
20 mM HEPES with either 5 mM CaCl2, 1 mM EGTA, or 5 mM 
CaCl2 and  peptide  at  500  nM  or  trifluoperazine  (TFP)  at  1µM 
unless otherwise noted. Peptides were obtained from Anaspec in 
≥95%  purity  and  the  small  molecule  TFP  was  obtained  from 
Sigma. Buffer was mixed with 125 nM protein and incubated for 
50 minutes at room temperature. Two ml of protein mixtures were 
then transferred to a cuvette and incubated in the Cary UV-Vis 
spectrophotometer (Agilent Technologies) with stirring for 10 min 
to equilibrate to 25°C or other assay temperature. At time zero,  
150 µM CENTA™ substrate (EMD Millipore) which was added to 
start  the  assay.  Product  concentration  was  determined  by 
monitoring  absorbance  at  405  nm  and  using  the  CENTA™ 
extinction  coefficient:  Δε  =  6400  M
-1  cm
-1  to  calculate  product 
concentrations.  To  determine  switching  activity,  assays  were 
performed  for  3  different  batches  of  purified  BLACaM  with 
multiple  runs  (n  =  3  to  8)  for  each  peptide  target  and  buffer 
condition.  V0  data  was  calculated  for  each  run  using  the  Cary 
WinUV  Software  and  batch  switching  activity  (V0
condition/V0
calcium) 
and standard deviation of the mean (SDM) determined. Reported 
SA values were then calculated using a weighted average of the 
three  batch’s  values.  Dose  dependent  V0  data  using  different 
concentrations of M13 peptide were averaged from multiple runs   6 
(n  =  4).  Alternatively,  assays  were  also  performed  in  96  well 
microassay  plates  using  the  same  concentrations  and  general 
procedures but with only 100 µl total volume and absorbances 
read using the Biotek Synergy H1 Hybrid plate reader. 
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SI Table 1: Primers used in cloning.  Primers were purchased from either Eurofins MWG Operon or 
Bioneer Corp. 
Primer Name  Primer Sequence (5’-3’) 
P1 and P2 Primers   
BLA sig (BglII)-for  GCACCCAGATCTCATATGAGTATTCAACATTTCCGTGTCGCCC 
BLA nosig(BglII)-for  GCACCCAGATCTCATATGCACCCAGAAACGCTGGTGAAAG 
BLA-rev  CCTACGACTAGTCTATTACCAATGCTTAATCAGTGAGGCACCTATCTC 
BLF1-DKS-rev  GGTCAGCTGATCTGCAGATTTATCGCCAGTTAATAGTTTGCGCAACGTTGTTGC 
Calm1-DKS-for  GGCGATAAATCTGCAGATCAGCTGACCGAAGAACAGATTGC 
Calm1-GSGGG-rev  CCGCCTCCGGACCCTTTTGCAGTCATCATCTGTACGAATTCTTCATAGTTGACTTGTCC 
BLF2-GSGGG- for  GCAAAAGGGTCCGGAGGCGGTCTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGG 
BLF1-Calm1-rev  GCTGATCTGCGCCAGTTAATAGTTTGCGCAACGTTGTTGC 
Calm1-BLF1-for  GCAAACTATTAACTGGCGCAGATCAGCTGACCGAAGAACAGATTGC 
Calm1-BLF2-rev  GCTAGAGTAAGTAGTTTTGCAGTCATCATCTGTACGAATTCTTCATAGTTGACTTGTCC 
BLF2-Calm1-for  CGTACAGATGATGACTGCAAAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGG 
BLA(SpeI)-rev  CCACGAAGCTTACTAGTCTATTACCAATGCTTAATCAGTGAGGCACCTATCTCAGC 
BLA sig (BamHI)-for  CGGTGGGATCCATATGAGTATTCAACATTTCCGTGTCGCCC 
P3 and P4 Primers   
BLF2-for  CGGTGGGATCCATATGCTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGG 
BLF2-DKS-Calm1-rev  GCTGATCTGCAGATTTATCCCAATGCTTAATCAGTGAGGCACCTATCTCAGC 
Calm1-DKS-BLF2-for  GCATTGGGATAAATCTGCAGATCAGCTGACCGAAGAACAGATTGC 
Calm1-GGSGG-rev  CCGCCTCCGGACCCTTTTGCAGTCATCATCTGTACGAATTCTTCATAGTTGACTTGTCC 
BLF1-GGSGG-Calm1-for  GCAAAAGGGTCCGGAGGCGGTCACCCAGAAACGCTGGTGAAAGTAAAAGATGC 
BLF2-Calm1-rev  CGGTCAGCTGATCTGCCCAATGCTTAATCAGTGAGGCACCTATCTCAGC 
Calm1-BLF2-for  GCATTGGGCAGATCAGCTGACCGAAGAACAGATTGC 
Calm1-BLF1-rev  CGTTTCTGGGTGTTTTGCAGTCATCATCTGTACGAATTCTTCATAGTTGACTTGTCC 
BLF1-Calm1-for  CGTACAGATGATGACTGCAAAACACCCAGAAACGCTGGTGAAAGTAAAAGATGC 
BLF1-rev  CCACGCACTAGTCTATTAGCCAGTTAATAGTTTGCGCAACGTTGTTGC 
P5 and P6 Primers   
Bla24(BamHI)-for  CGG TGG GAT CC TAT GCA CCC AGA AAC GCT GGT GAA AGT AAA AGA TGC 
BLA226-DKS-Calm1-rev  GCTGATCTGCAGATTTATCAGCCGGAAGGGCCGAGC 
Calm1-DKS-BLA226-for  CCGGCTGATAAATCTGCAGATCAGCTGACCGAAGAACAGATTGC 
Calm1-GGSGG-rev  CCGCCTCCGGACCCTTTTGCAGTCATCATCTGTACGAATTCTTCATAGTTGACTTGTCC 
BLA227-link-Calm1-for  GCAAAAGGGTCCGGAGGCGGTGGCTGGTTTATTGCTGATAAATCTGGAGCC 
BLA226-Calm1-rev  GCTGATCTGCAGAAGCCGGAAGGGCCGAGC 
Calm1 -BLA226-for  CCTTCCGGCTTCTGCAGATCAGCTGACCGAAGAACAGATTGC 
Calm1-BLA227-rev  GCCTCCGGATTTTGCAGTCATCATCTGTACGAATTCTTCATAGTTGACTTGTCC 
BLA227-Calm1-for  CGTACAGATGATGACTGCAAAATCCGGAGGCTGGTTTATTGCTGATAAATCTGGAGC 
BLA(SpeI)-rev  CCACGAAGCTTACTAGTCTATTACCAATGCTTAATCAGTGAGGCACCTATCTCAGC 
P7 and P8 primers   
Bla24(BamHI)-for  CGG TGG GAT CC TAT GCA CCC AGA AAC GCT GGT GAA AGT AAA AGA TGC 
BLA170-DKS-Calm1-rev  GGTCAGCTGATCTGCAGATTTATCGGCTTCATTCAGCTCCGGTTCC 
Calm1-DKS-BLA170-for  CCGATAAATCTGCAGATCAGCTGACCGAAGAACAGATTGC 
Calm1-GGSGG-rev  CCGCCTCCGGACCCTTTTGCAGTCATCATCTGTACGAATTCTTCATAGTTGACTTGTCC 
BLA170-GSGGG-Calm1-for  GCAAAAGGGTCCGGAGGCGGTGCCATACCAAACGACGAGCG 
BLA170-Calm1-rev  GCTGATCTGCAGAGGCTTCATTCAGCTCCGGTTCCC 
Calm1-BLA170-for  GCTGAATGAAGCCTCCTGCAGATCAGCTGACCGAAGAACAGATTGC 
Calm1-BLA170-rev  GCTCCGGATTTTGCAGTCATCATCTGTACGAATTCTTCATAGTTGACTTGTCC 
BLA170-Calm1-for  CGTACAGATGATGACTGCAAAATCCGGAGCCATACCAAACGACGAGCGTGACACC 
BLA(SpeI)-rev  CCACGAAGCTTACTAGTCTATTACCAATGCTTAATCAGTGAGGCACCTATCTCAGC 
Control and Expression 
Primers 
 
Calm1(BamHI)-for  GAGGAAGGATCCATGGCAGATCAGCTGACCGAAGAACAGATTGC 
Calm1(SpeI)-rev  CGACTAACTAGTCTATCATTTTGCAGTCATCATCTGTACGAATTCTTCATAGTTGAC 
CaMopt-for  CTGTCAGGATCCATATGGCAGATCAGCTGACCGAAGAACAG 
CaMopt(XhoI)-rev  ACGTCACTCGAGTTTTGCAGTCATCATCTGTACGAATTCTTCATAG 
BLA2opt-for  CTGTCAGGATCCATATGCTGCTTACTCTGGCTTCCCGC 
BLA1opt(XhoI)-rev  ACGTCACTCGAGGCCAGTTAACAGTTTGCGCAACG 2 
 
 
 
Figure S1. Schematic of β-lactamase-calmodulin fusions. Calmodulin (blue) fused to either PCA 
fragments BLF1 (purple) and BLF2 (green), or other BLA fragments (grey). P1 and P2 also 
contain the wt-BLA periplasmic export sequence (orange). 
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Figure S2. SDS-PAGE confirming the purity of BLACaM after codon optimization, expression in E. coli, 
and affinity purification.   4 
 
 
Figure S3.  Buffer condition effects on CENTA™  hydrolysis activity of wt-BLA and wt-CaM 
proteins.  Substrate  hydrolysis  by  BLA, CaM,  and BLA and CaM combined is monitored as 
absorbance at 405 nm in conditions such as (a) EGTA or calcium only and (b) calcium and the 
peptides  M13 (smMLCK), mastoparan, mellitin, δ-toxin, neuropeptide Y (NPY),  luteinizing- 
hormone releasing-hormone (LH-RH), angiotensin, and small molecule trifluoperazine (TFP).    
   5 
 
 
Figure S4. Results from control experiments to monitor the propensity for BLACaM fragments to 
spontaneously assemble in an intermolecular fashion and reconstitute an active enzyme. a) Schematic 
depicting the BLACaM fragments BLF1-CaM and CaM-BLF21. b) SDS page gel of the purified fragments 
after expression in E. coli and affinity purification. c) Total substrate hydrolysis was monitored in HEPES 
buffer for each of the fragments individually and combined at varying equimolar concentrations. Sample 
absorbances were normalized to blank samples of the assay substrate in the absence of any enzyme. 6 
 
 
Figure S5. Optimization of activity assay conditions for BLACaM. a) Hydrolysis of CENTA™ 
substrate by BLACaM was monitored directly after the purification procedure after incubation for 
different lengths of time in the presence of 5 mM calcium. b) Comparison of BLACaM activity 
after preincubation for 60 min with calcium alone (red), or calcium plus M13 (purple). In order to 
monitor enzyme activation in real time, the assay was also performed with a preincubation for 
60 min in calcium alone and addition of M13 to the assay solution 5 min after the start of the 
assay (green).  
 7 
 
 
 
Figure S6. Effects of temperature on BLACaM activity. a) BLACaM with either 5 mM calcium 
(purple) or 5 mM calcium and M13 (green) was preincubated at 37°C for 10 min in 5 mM Ca
2+, 
then equilibrated at 25°C before CENTA™  assays were performed  at 25°C. Alternatively 
BLACaM was preincubated with calcium for 50 minutes at room temperature, followed by a 10 
min equilibration  at  either 20, 25, 30 or 37°C  before assays were performed  at the same 
temperatures. Assays were preformed in the presence of 1 mM EGTA (b), 5 mM calcium (c), or 
5 mM calcium plus 500 nM M13 peptide (d).   
 